Conference abstract · 21 May 2021
Short communicationPublished 17 Dec 2020
A Short Note on Ledipasvir Sofosbuvir
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Ledipasvir sold below the brand Harvoni among others, may be a medication accustomed treat viral hepatitis. It's a fixeddose combination of ledipasvir and sofosbuvir. Cure rates are ninety four to ninety nine in individuals infected with viral hepatitis virus (HCV) genotype one. Some proof additionally supports use in HCV genotype three and four. It’s taken daily orally for 8–24 weeks. It is usually well tolerated. Common aspect effects embrace muscle pains, headache, nausea, rash, and cough. It is unclear if use in physiological state is safe for the baby. Ledipasvir works by decreasing the activity of NS5A and sofosbuvir works by decreasing the activity of NS5B enzyme.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 16 Sep 2019
Resistant HCV Variant after cure treatment with Ledipasvir/Sofosbuvir in a patient with chronic Hepatitis C
Conference abstract · 6 Dec 2018
The effectiveness of oral antiviral (Sofosbuvir/ledipasvir) in treating children with HCV infection
Editorial · 16 Oct 2017
Ombitasvir/paritaprevir/ritonavir plus weight based ribavirin versus ledipasvir/sofosbuvir fixed dose combination in treatment of HCV genotype IV in a patient with idiopathic pulmonary hypertension and renal impairment
Conference abstract · 7 Aug 2017
Chromatographic analysis of ledipasvir and sofosbuvir: New treatment for chronic hepatitis C infection with application to human plasma
More from this journal
The newest in Journal of Liver: Disease & Transplantation.
Opinion · 30 Dec 2024
Gut Microbiome and Its Role in the Progression of Liver Fibrosis
Opinion · 30 Dec 2024
Epidemiology of Alcohol-Associated Liver Disease: Trends and Implications for Public Health
Opinion · 30 Dec 2024
Advances in Regenerative Medicine and Stem Cell Therapies for Liver Cirrhosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Liver: Disease & Transplantation
- SubjectGastroenterology & Hepatology
- SubjectSurgery
- BylineArticles whose byline prints “Sharath Kumar”

